title: Prospects of antisense oligodeoxynucleotides to alleviate renal ischaemia-reperfusion injury.
abstract: Renal ischaemia-reperfusion (I/R) injury is a clinically significant problem and an invariable consequence of renal transplantation. The problem begins at the onset of acute tubular necrosis (ATN), when the transplantation takes a long ischaemic interval by using the cardiac arrest donor's kidney. In addition, the longer the ischaemic interval, the higher the incidence rate of ATN. It is clinically important that renal I/R injury is reduced. The antisense oligodeoxynucleotide (AS-ODN), developed as a therapy for intractable diseases at the gene level, has recently been established as an important method in examining specific gene functions. The authors have previously demonstrated that AS-ODN/tissue factor (TF) prevents renal I/R injury. This review discusses the efficacy of AS-ODN/TF and AS-ODN/intercellular adhesion molecule-1 as existing targets, and the potential of AS-ODN/nuclear factor-kappaB, AS-ODN/cyclooxygenase and AS-ODN/5-lipoxygenase as prospective targets.
authors.affiliation: Osaka City University Graduate School of Medicine, Department of Urology, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
authors.forename: Masahide
authors.initials: M
authors.lastname: Matsuyama
authors.forename: Rikio
authors.initials: R
authors.lastname: Yoshimura
mesh_terms: D000818:Animals; D018390:Gene Targeting / Q000379:methods; D006801:Humans; D007668:Kidney / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000627:therapeutic use*; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D016376:Oligonucleotides, Antisense